title: Effects of Lovastatin on MDA-MB-231 Breast Cancer Cells: An Antibody Microarray Analysis.
abstract: Despite the tremendous improvement in cancer therapeutics, treatment of late-stage breast cancer remains a challenge for both basic scientists and clinicians. Lovastatin, a natural product derived from Aspergillus terreus or Monascus ruber, has been widely used as cholesterol-lowing drug in the clinic. It also has anti-cancer properties through poorly defined molecular mechanisms. In the present study, we employed a novel antibody microarray technology to investigate the molecular mechanisms through which lovastatin inhibits breast cancer. We found that lovastatin up-regulated 17 proteins and down-regulated 20 proteins in MDA-MB-231 breast cancer cells. These included proteins that modulate apoptosis, cell proliferation, differentiation, signal transduction, epithelial-to-mesenchymal transition and tumor metastasis. Modulation of these pathways may mediate, in part, the inhibitory activity of lovastatin on breast cancer.
authors.affiliation: 1. National Engineering Laboratory for Rice and Byproduct Deep Processing, Central South University of Forestry and Technology, Changsha, Hunan 410004, China;
authors.forename: Tao
authors.initials: T
authors.lastname: Yang
authors.affiliation: 2. Medical College, Hunan Normal University, Changsha, Hunan 410013, China;
authors.forename: Hui
authors.initials: H
authors.lastname: Yao
authors.affiliation: 2. Medical College, Hunan Normal University, Changsha, Hunan 410013, China;
authors.forename: Guangchun
authors.initials: G
authors.lastname: He
authors.affiliation: 2. Medical College, Hunan Normal University, Changsha, Hunan 410013, China;
authors.forename: Liujiang
authors.initials: L
authors.lastname: Song
authors.affiliation: 2. Medical College, Hunan Normal University, Changsha, Hunan 410013, China;
authors.forename: Ning
authors.initials: N
authors.lastname: Liu
authors.affiliation: 1. National Engineering Laboratory for Rice and Byproduct Deep Processing, Central South University of Forestry and Technology, Changsha, Hunan 410004, China;
authors.forename: Yan
authors.initials: Y
authors.lastname: Wang
authors.affiliation: 3. College of Biology, Hunan University, Changsha, Hunan 410082, China.
authors.forename: Yingke
authors.initials: Y
authors.lastname: Yang
authors.affiliation: 4. Department of Urology, University of Michigan, Ann Arbor, MI 48109, USA.
authors.forename: Evan T
authors.initials: ET
authors.lastname: Keller
authors.affiliation: 2. Medical College, Hunan Normal University, Changsha, Hunan 410013, China;
authors.forename: Xiyun
authors.initials: X
authors.lastname: Deng
keywords: Antibody microarray; Breast cancer; Hypoxia; Lovastatin; Natural products
references.citation: Lancet Oncol. 2014 Jun;15(7):e279-89
references.pmid: 24872111
references.citation: Clin Cancer Res. 2009 May 1;15(9):3076-83
references.pmid: 19383813
references.citation: Breast Cancer Res. 2010;12(2):R16
references.pmid: 20205716
references.citation: Cancer Epidemiol Biomarkers Prev. 2008 May;17(5):1028-33
references.pmid: 18463402
references.citation: Int J Cancer. 2008 Jan 1;122(1):209-18
references.pmid: 17847032
references.citation: Breast Cancer Res. 2013 Feb 25;15(1):202
references.pmid: 23673317
references.citation: Pharm Res. 2001 Jun;18(6):800-6
references.pmid: 11474784
references.citation: J Neurochem. 1996 Feb;66(2):710-6
references.pmid: 8592143
references.citation: J Gastroenterol Hepatol. 2013 Mar;28(3):401-5
references.pmid: 23173651
references.citation: J Biol Chem. 2006 Mar 3;281(9):5532-8
references.pmid: 16407273
references.citation: Cancer Gene Ther. 2005 Mar;12(3):228-37
references.pmid: 15550937
references.citation: Int J Mol Med. 2009 Jul;24(1):3-8
references.pmid: 19513527
references.citation: Oncol Rep. 2013 Apr;29(4):1356-64
references.pmid: 23443464
references.citation: Anticancer Drugs. 2014 Aug;25(7):735-44
references.pmid: 24637578
references.citation: Clin Cancer Res. 1999 Aug;5(8):2223-9
references.pmid: 10473109
references.citation: J Cell Mol Med. 2013 Jan;17 (1):30-54
references.pmid: 23301832
references.citation: CA Cancer J Clin. 2015 Mar;65(2):87-108
references.pmid: 25651787
references.citation: Breast Cancer Res Treat. 2008 Jun;109(3):573-9
references.pmid: 17674197
references.citation: Leuk Res. 2001 Aug;25(8):651-60
references.pmid: 11397469
references.citation: J Cancer. 2015 Apr 05;6(6):511-8
references.pmid: 26000041
references.citation: Toxins (Basel). 2014 Jul 25;6(8):2210-28
references.pmid: 25068924
references.citation: Clin Cancer Res. 2000 May;6(5):2044-52
references.pmid: 10815931
references.citation: Front Chem. 2014 May 01;2:20
references.pmid: 24822174
references.citation: FEBS J. 2011 Dec;278(24):4756-67
references.pmid: 22051117
references.citation: Cancer Res. 2006 Sep 1;66(17):8707-14
references.pmid: 16951186
references.citation: Clin Cancer Res. 2003 Jan;9(1):10-9
references.pmid: 12538446
references.citation: Eur J Cancer. 1998 Feb;34(3):406-11
references.pmid: 9640231
references.citation: Cancer Lett. 2008 Feb 18;260(1-2):11-9
references.pmid: 18180097
references.citation: Cancer Metastasis Rev. 2012 Dec;31(3-4):733-51
references.pmid: 22752409
references.citation: Clin Cancer Res. 2001 Jan;7(1):158-67
references.pmid: 11205904
references.citation: Nat Rev Drug Discov. 2011 Jun 24;10 (7):507-19
references.pmid: 21701501
references.citation: Ageing Res Rev. 2013 Jan;12(1):1-7
references.pmid: 22504583
references.citation: Am J Cancer Res. 2013 Nov 01;3(5):500-8
references.pmid: 24224127
references.citation: Int J Cancer. 1999 May 17;81(4):560-7
references.pmid: 10225445